We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
- Authors
Livermore, David M.; Mushtaq, Shazad; Warner, Marina; Vickers, Anna; Woodford, Neil
- Abstract
<bold>Objectives: </bold>Diazabicyclooctanes (DBOs) inhibit class A, class C and some class D β-lactamases. A few also bind PBP2, conferring direct antibacterial activity and a β-lactamase-independent 'enhancer' effect, potentiating β-lactams targeting PBP3. We tested a novel DBO, zidebactam, combined with cefepime.<bold>Methods: </bold>CLSI agar dilution MICs were determined with cefepime/zidebactam in a chequerboard format. Bactericidal activity was also measured.<bold>Results: </bold>Zidebactam MICs were ≤2 mg/L (mostly 0.12-0.5 mg/L) for most Escherichia coli , Klebsiella , Citrobacter and Enterobacter spp., but were >32 mg/L for Proteeae, most Serratia and a few E. coli , Klebsiella and Enterobacter/Citrobacter . The antibacterial activity of zidebactam dominated chequerboard studies for Enterobacteriaceae, but potentiation of cefepime was apparent for zidebactam-resistant isolates with class A and C enzymes, illustrating β-lactamase inhibition. Overall, cefepime/zidebactam inhibited almost all Enterobacteriaceae with AmpC, ESBL, K1, KPC and OXA-48-like β-lactamases at 1 + 1 mg/L and also 29 of 35 isolates with metallo-carbapenemases, including several resistant to zidebactam alone. Zidebactam MICs for 36 of 50 Pseudomonas aeruginosa were 4-16 mg/L, and the majority of AmpC, metallo-β-lactamase-producing and cystic fibrosis isolates were susceptible to cefepime/zidebactam at 8 + 8 mg/L. Zidebactam MICs for Acinetobacter baumannii and Stenotrophomonas maltophilia were >32 mg/L; potentiation of cefepime was frequent for S. maltophilia , but minimal for A. baumannii . Kill curve results largely supported MICs.<bold>Conclusions: </bold>Zidebactam represents a second triple-action DBO following RG6080, with lower MICs for Enterobacteriaceae and P. aeruginosa . Clinical evaluation of cefepime/zidebactam must critically evaluate the reliance that can be placed on this direct antibacterial activity and on the enhancer effect as well as β-lactamase inhibition.
- Subjects
DIAZABICYCLOOCTANE; BETA lactamases; ANTIBACTERIAL agents; LACTAMS; CEFEPIME; GRAM-negative bacteria; THERAPEUTICS; ANTIBIOTICS; CEPHALOSPORINS; ENTEROBACTERIACEAE; ENZYME inhibitors; ESCHERICHIA coli; HYDROCARBONS; KLEBSIELLA; MICROBIAL sensitivity tests; ORGANIC compounds; PIPERIDINE; CITROBACTER; ENTEROBACTERIACEAE diseases; PHARMACODYNAMICS
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2017, Vol 72, Issue 5, p1373
- ISSN
0305-7453
- Publication type
journal article
- DOI
10.1093/jac/dkw593